The investigation compared the characteristics of HER2-low and HER2-zero BC cases and revealed minimal prognostic disparities, implying that the effectiveness of HER2-directed therapies will play a crucial role in shaping outcomes, rather than inherent biological differences associated with low levels of HER2 expression. The gene discussed is ERBB2; the disease is breast cancer.